"Immunity, Cellular" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role.
| Descriptor ID |
D007111
|
| MeSH Number(s) |
G12.450.050.400
|
| Concept/Terms |
Immunity, Cellular- Immunity, Cellular
- Cellular Immunities
- Cellular Immunity
- Immunities, Cellular
- Cell-Mediated Immunity
- Cell Mediated Immunity
- Cell-Mediated Immunities
- Immunities, Cell-Mediated
- Immunity, Cell-Mediated
Cellular Immune Response- Cellular Immune Response
- Cellular Immune Responses
- Immune Response, Cellular
- Immune Responses, Cellular
- Response, Cellular Immune
|
Below are MeSH descriptors whose meaning is more general than "Immunity, Cellular".
Below are MeSH descriptors whose meaning is more specific than "Immunity, Cellular".
This graph shows the total number of publications written about "Immunity, Cellular" by people in this website by year, and whether "Immunity, Cellular" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 1 | 2 | 3 |
| 2006 | 0 | 1 | 1 |
| 2011 | 1 | 1 | 2 |
| 2016 | 1 | 2 | 3 |
| 2017 | 0 | 1 | 1 |
| 2018 | 0 | 1 | 1 |
| 2019 | 0 | 2 | 2 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunity, Cellular" by people in Profiles.
-
T cell responses to SARS-CoV-2 spike cross-recognize Omicron. Nature. 2022 03; 603(7901):488-492.
-
A global scientific strategy to cure hepatitis B. Lancet Gastroenterol Hepatol. 2019 07; 4(7):545-558.
-
A child with perinatal HIV infection and long-term sustained virological control following antiretroviral treatment cessation. Nat Commun. 2019 01 24; 10(1):412.
-
Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). Lancet. 2018 07 21; 392(10143):232-243.
-
The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial. PLoS Negl Trop Dis. 2017 May; 11(5):e0005440.
-
Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap. Clin Vaccine Immunol. 2016 06; 23(6):496-506.
-
Serotype-Specific Cell-Mediated Immunity Associated With Clearance of Homotypic Group B Streptococcus Rectovaginal Colonization in Pregnant Women. J Infect Dis. 2016 06 15; 213(12):1923-6.
-
Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention: A Randomized Trial. Ann Intern Med. 2016 Mar 01; 164(5):313-22.
-
Anti-nucleocapsid protein immune responses counteract pathogenic effects of Rift Valley fever virus infection in mice. PLoS One. 2011; 6(9):e25027.
-
Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet Infect Dis. 2011 Jul; 11(7):507-15.